3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
18
Recruiting
3
Terminated
2
Unknown
1
Active not recruiting
1
Sponsor Class
OTHER
15
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Classical hematology
2
Gastrointestinal
1
Conditions
Neoplasms
474
Carcinoma, Non-Small-Cell Lung
449
Breast Neoplasms
331
Neoplasm Metastasis
243
Colorectal Neoplasms
214
Melanoma
213
Leukemia, Myeloid, Acute
191
Multiple Myeloma
180
Recurrence
169
Ovarian Neoplasms
169
Prostatic Neoplasms
163
Lymphoma, Non-Hodgkin
149
Lung Neoplasms
134
Pancreatic Neoplasms
125
Lymphoma
124
Carcinoma, Renal Cell
112
Leukemia, Lymphocytic, Chronic, B-Cell
111
Squamous Cell Carcinoma of Head and Neck
110
Stomach Neoplasms
92
Carcinoma, Hepatocellular
89
Lymphoma, Large B-Cell, Diffuse
88
Leukemia
88
Triple Negative Breast Neoplasms
86
Lymphoma, Follicular
82
Head and Neck Neoplasms
79
Glioblastoma
75
Myelodysplastic Syndromes
70
Urinary Bladder Neoplasms
68
Small Cell Lung Carcinoma
64
Precursor Cell Lymphoblastic Leukemia-Lymphoma
55
Interventions
abelacimab
2
MAA868
2
apixaban
1
Dalteparin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
INDUSTRY
×
Venous Thromboembolism
×
Clear all
NCT05171075
2026-04-17
MAGNOLIA
Anthos Therapeutics, Inc.
Phase 3
Terminated
417 enrolled
NCT05171049
2026-02-23
ASTER
Anthos Therapeutics, Inc.
Phase 3
Terminated
1,150 enrolled